Ovarian Cancer Studies Elusive: Should Erlotinib Be Added to Chemotherapy?
13th Nov 2006, 16:14 GMT
Researchers are questioning whether adding erlotinib to the standard first-line regimen of paclitaxel and carboplatin encourages pathologic complete response in patients with ovarian, fallopian tube, or primary peritoneal cancers. Medscape Medical News Allison Gandey
Ovarian Cancer Studies Elusive: Should Erlotinib Be Added to Chemotherapy? related news:
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
- Babies still an option for those with ovarian cancer? — Blogging Baby
- Diet can provide protection against development of certain cancers, new studies show — EurekAlert! - Breaking News
- NICE disapproves the use of cancer drug Tarceva — The Earth Times Online Newspaper
- Risk after colon cancer higher for the very fat and very thin — EurekAlert! - Breaking News
- Studies Look At Diet's Ties To Cancer, Heart Risks — wnbc.com - Health
- Other highlights in the November 15 JNCI — EurekAlert! - Biology
- Have wig, will share — The Cancer Blog
- Executive Q&A: Sara Sinaiko - Helping heal those touched by cancer — madison.com - RSS
- Plant-derived molecules, genetic manipulation point to future chemoprevention methods — EurekAlert! - Medicine and Health